Seronegative Propylthiouracil‐Induced Reversible Bilateral Sensory Neural Hearing Loss Without Systemic Vasculitis: A Case Report and Review of Literature
- 1Department Internal Medicine, Asrat Weldeyes Health Sciences College Debre Berhan University Debre Berhan Ethiopia.
- 2Department of Otolaryngology Head and Neck Surgery Addis Ababa University Addis Ababa Ethiopia.
Abstract
Propylthiouracil (PTU) is a thioamide drug used in the management of hyperthyroidism in selected clinical settings. While PTU is associated with well-known adverse effects such as hepatotoxicity, agranulocytosis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ototoxicity is an exceptionally rare complication. We present a case of reversible bilateral sensorineural hearing loss following PTU therapy in the absence of systemic vasculitis. A 42-year-old Ethiopian woman with newly diagnosed Graves' disease was commenced on PTU 100 mg orally three times daily and propranolol 40 mg daily. After approximately two months of PTU therapy, the patient developed gradual onset bilateral hearing loss which worsened within 2 weeks before she presented for evaluation accompanied by tinnitus, without vertigo or prior history of ear disease, noise exposure, or use of other ototoxic medications. Physical examination revealed diffuse, nontender goiter and bilateral eighth cranial nerve palsy, with normal otoscopic findings. Audiometric evaluation demonstrated bilateral, symmetric, down-sloping high-frequency sensorineural hearing loss, with normal hearing thresholds at low and mid frequencies and moderate-to-severe hearing loss at 4-8 kHz. Laboratory work-up excluded infectious, autoimmune, and metabolic causes, including negative ANCA and antinuclear antibody serologies. PTU was discontinued and a short course of oral prednisolone (40 mg daily for five days) was initiated. Hearing began to improve within days and normalized completely by day ten, confirmed by follow-up audiometry. This case highlights PTU-induced ototoxicity as a rare but reversible adverse event, even in the absence of systemic vasculitis or ANCA positivity. Clinicians should maintain a high index of suspicion for auditory symptoms in patients on PTU therapy. Early recognition and prompt drug withdrawal are essential to prevent permanent hearing impairment. Based on the WHO-UMC causality assessment criteria, this adverse reaction was classified as probable/likely.
Related
- Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack
- C5a drives central nervous system vasculitis in endothelial cells and fibroblasts via modulating the PI3K/ERK/CREB signaling pathways
- Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database
- Multimodal Profiling of Complement Expression and Association With Outcomes in ANCA-Associated Vasculitis With Glomerulonephritis
- Phenotypic characterization of patients with ANCA-associated vasculitis and diffuse alveolar hemorrhage: a data-driven analysis of a multicentre, retrospective, nationwide cohort
BibTeX
@article{abera2026seronegative,
title = {{Seronegative Propylthiouracil‐Induced Reversible Bilateral Sensory Neural Hearing Loss Without Systemic Vasculitis: A Case Report and Review of Literature}},
author = {Adane Alemayehu Abera and Genetu Dagnaw Alemayehu and Zelalem Tadesse Wondimu and Behaylu Tesfamaryam Hagos and Mequannet Tesfaw Addis and Mohammedsefa Arusi Dari},
journal = {Clinical case reports},
year = {2026},
month = oct,
doi = {10.1002/ccr3.73722},
url = {https://europepmc.org/article/PMC/PMC13718940},
note = {CC BY},
}
RIS
TY - JOUR
TI - Seronegative Propylthiouracil‐Induced Reversible Bilateral Sensory Neural Hearing Loss Without Systemic Vasculitis: A Case Report and Review of Literature
AU - Adane Alemayehu Abera
AU - Genetu Dagnaw Alemayehu
AU - Zelalem Tadesse Wondimu
AU - Behaylu Tesfamaryam Hagos
AU - Mequannet Tesfaw Addis
AU - Mohammedsefa Arusi Dari
PY - 2026
DA - 2026/10/29
JO - Clinical case reports
DO - 10.1002/ccr3.73722
UR - https://europepmc.org/article/PMC/PMC13718940
AB - Propylthiouracil (PTU) is a thioamide drug used in the management of hyperthyroidism in selected clinical settings. While PTU is associated with well-known adverse effects such as hepatotoxicity, agranulocytosis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ototoxicity is an exceptionally rare complication. We present a case of reversible bilateral sensorineural hearing loss following PTU therapy in the absence of systemic vasculitis. A 42-year-old Ethiopian woman with newly diagnosed Graves' disease was commenced on PTU 100 mg orally three times daily and propranolol 40 mg daily. After approximately two months of PTU therapy, the patient developed gradual onset bilateral hearing loss which worsened within 2 weeks before she presented for evaluation accompanied by tinnitus, without vertigo or prior history of ear disease, noise exposure, or use of other ototoxic medications. Physical examination revealed diffuse, nontender goiter and bilateral eighth cranial nerve palsy, with normal otoscopic findings. Audiometric evaluation demonstrated bilateral, symmetric, down-sloping high-frequency sensorineural hearing loss, with normal hearing thresholds at low and mid frequencies and moderate-to-severe hearing loss at 4-8 kHz. Laboratory work-up excluded infectious, autoimmune, and metabolic causes, including negative ANCA and antinuclear antibody serologies. PTU was discontinued and a short course of oral prednisolone (40 mg daily for five days) was initiated. Hearing began to improve within days and normalized completely by day ten, confirmed by follow-up audiometry. This case highlights PTU-induced ototoxicity as a rare but reversible adverse event, even in the absence of systemic vasculitis or ANCA positivity. Clinicians should maintain a high index of suspicion for auditory symptoms in patients on PTU therapy. Early recognition and prompt drug withdrawal are essential to prevent permanent hearing impairment. Based on the WHO-UMC causality assessment criteria, this adverse reaction was classified as probable/likely.
SN - 2050-0904
ER -